Citations

Clear

1727 citation(s) found for "So, Alan".

Impact of Clinical Pharmacists in Inflammatory Bowel Disease Centers During the COVID-19 Pandemic
Bhat, Shubha , Moss, Alan C. , Farraye, Francis A.

Mayo Clinic

American Journal of Gastroenterology | July 21, 2020 | Volume: 115 | Issue: 9 | Pages: 1532-1533

10.14309/ajg.0000000000000787 | PMID 32694291 Get It

INTRODUCTION: To characterize the clinical pharmacists' impact on caring for patients with inflammatory bowel disease during COVID-19. METHODS: A clinical pharmacist's encounters between March 17 and April 14, 2020, were audited to determine encounter frequency and indication. RESULTS: The clinical pharmacist addressed COVID-19 and inflammatory bowel disease treatment concerns with 140 patients, conducted 34 medication education and monitoring visits, reviewed 141 patients' charts and helped rescheduled 18 patients who missed their biologic infusion, transitioned 12 patients to home infusions, and assisted 5 patients with medication access. DISCUSSION: Clinical pharmacists embedded in gastroenterology practices permit for continued optimal patient care during a pandemic.
99th Percentile Upper-Reference Limit of Cardiac Troponin and the Diagnosis of Acute Myocardial Infarction
Sandoval, Yader , Apple, Fred S. , Saenger, Amy K., Wu, Alan H.B. , Jaffe, Allan S. , Collinson, Paul , Jaffe, Allan S.

Mayo Clinic

Clinical Chemistry | July 8, 2020 | Volume: 66 | Issue: 9 | Pages: 1167-1180

10.1093/clinchem/hvaa158 | PMID 32871000 Get It

Abstract Background Concerns exist regarding how the 99th percentile upper reference limit (URL) of cardiac troponin (cTn) is determined and whether it should be derived from normal healthy individuals. Content The 99th percentile URL of cTn is an important criterion to standardize the diagnosis of myocardial infarction (MI) for clinical, research, and regulatory purposes. Statistical heterogeneity in its calculation exists but recommendations have been proposed. Some negativity has resulted from the fact that with some high-sensitivity (hs) cTn assays, a greater number of increases above the 99th percentile are observed when transitioning from a contemporary assay. Increases reflect acute or chronic myocardial injury and provide valuable diagnostic and prognostic information. The etiology of increases can sometimes be difficult to determine, making a specific treatment approach challenging. For those reasons, some advocate higher cutoff concentrations. This approach can contribute to missed diagnoses. Contrary to claims, neither clinical or laboratory guidelines have shifted away from the 99th percentile. To support the diagnosis of acute MI, the 99th percentile URL remains the best-established approach given the absence of cTn assay standardization. Importantly, risk stratification algorithms using hs-cTn assays predict the possibility of MI diagnoses established using the 99th percentile. Summary The 99th percentile of cTn remains the best-established criterion for the diagnosis of acute MI. While not perfect, it is analytically and clinically evidence-based. Until there are robust data to suggest some other approach, staying with the 99th percentile, a threshold that has served the field well for the past 20 years, appears prudent.
Genome-Wide Association Study Data Reveal Genetic Susceptibility to Chronic Inflammatory Intestinal Diseases and Pancreatic Ductal Adenocarcinoma Risk
Yuan, Fangcheng , Hung, Rayjean J. , Walsh, Naomi , Wheeler, William , Song, Lei , Arslan, Alan A. , Bracci, Paige M. , Du, Mengmeng , Gallinger, Steven , Goodman, Phyllis J. , Scélo, Ghislaine , Visvanathan, Kala , Andreotti, Gabriella , Babić, Ana , Berndt, Sonja I. , Brennan, Paul , Bueno‐de‐Mesquita, Bas , Buring, Julie E. , Fuchs, Charles S. , Gaziano, J. Michael , Hackert, Thilo , Hartge, Patricia, Hassan, Manal M. , Holly, Elizabeth A. , Hoover, Robert N. , Kirsten, Holger , Kurtz, Robert C. , Lee, I‐Min , Murphy, Neil , Ng, Kimmie , Oberg, Ann L. , Porta, Miquel , Rabe, Kari G. , Real, Francisco X. , Rothman, Nathaniel , Sesso, Howard D. , Thompson, Ian M. , Wactawski‐Wende, Jean , Wentzensen, Nicolas , Zeleniuch‐Jacquotte, Anne , Shi, Jianxin , Li, Donghui , Petersen, Gloria M. , Wolpin, Brian M. , Platz, Elizabeth A. , Arslan, Alan A , Canzian, Federico , Giles, Graham G , Bamlet, William R , Brennan, Paul , Hackert, Thilo , Katzke, Verena , Kirsten, Holger , Malats, Nuria , Milne, Roger L , Oberg, Ann L , Wactawski-Wende, Jean , Yu, Herbert , Duell, Eric J , Amundadottir, Laufey , Li, Donghui , Klein, Alison P , Stolzenberg-Solomon, Rachael , Chaffee, Kari G. , Hung, Rayjean J , Visvanathan, Kala , Yuan, Fangcheng , Murphy, Neil , Porta, Miquel , Real, Francisco X , Thompson, Ian M , Zeleniuch-Jacquotte, Anne , Zhang, Han , Freeman, Laura E. Beane , Canzian, Federico , Giles, Graham G. , Kooperberg, Charles , Marchand, Loı̈c Le , Neale, Rachel Ε. , Rosendahl, Jonas , Shu, Xiao‐Ou , White, Emily , Zheng, Wei , Albanes, Demetrius , Amiano, Pilar , Bamlet, William R. , Campbell, Peter T. , Chanock, Stephen Jacob , Goggins, Michael , Malats, Núria , Milne, Roger L. , Silverman, Debra T. , Wang, Xiaoliang , Wilkens, Lynne R. , Yu, Kai , Duell, Eric J. , Ámundadóttir, Laufey T. , Risch, Harvey A. , Klein, Alison P. , Stolzenberg‐Solomon, Rachael Z.

Mayo Clinic

Cancer Research | July 8, 2020 | Volume: 80 | Issue: 18 | Pages: 4004-4013

10.1158/0008-5472.can-20-0447 | PMID 32641412 Get It

Abstract Registry-based epidemiologic studies suggest associations between chronic inflammatory intestinal diseases and pancreatic ductal adenocarcinoma (PDAC). As genetic susceptibility contributes to a large proportion of chronic inflammatory intestinal diseases, we hypothesize that the genomic regions surrounding established genome-wide associated variants for these chronic inflammatory diseases are associated with PDAC. We examined the association between PDAC and genomic regions (±500 kb) surrounding established common susceptibility variants for ulcerative colitis, Crohn's disease, inflammatory bowel disease, celiac disease, chronic pancreatitis, and primary sclerosing cholangitis. We analyzed summary statistics from genome-wide association studies data for 8,384 cases and 11,955 controls of European descent from two large consortium studies using the summary data-based adaptive rank truncated product method to examine the overall association of combined genomic regions for each inflammatory disease group. Combined genomic susceptibility regions for ulcerative colitis, Crohn disease, inflammatory bowel disease, and chronic pancreatitis were associated with PDAC at P values < 0.05 (0.0040, 0.0057, 0.011, and 3.4 × 10−6, respectively). After excluding the 20 PDAC susceptibility regions (±500 kb) previously identified by GWAS, the genomic regions for ulcerative colitis, Crohn disease, and inflammatory bowel disease remained associated with PDAC (P = 0.0029, 0.0057, and 0.0098, respectively). Genomic regions for celiac disease (P = 0.22) and primary sclerosing cholangitis (P = 0.078) were not associated with PDAC. Our results support the hypothesis that genomic regions surrounding variants associated with inflammatory intestinal diseases, particularly, ulcerative colitis, Crohn disease, inflammatory bowel disease, and chronic pancreatitis are associated with PDAC. Significance: The joint effects of common variants in genomic regions containing susceptibility loci for inflammatory bowel disease and chronic pancreatitis are associated with PDAC and may provide insights to understanding pancreatic cancer etiology.
Comparing Clinical Characteristics and Outcomes in Patients with Non-Cystic Fibrosis Bronchiectasis with Non-Tuberculous Mycobacteria and/or Pseudomonas Aeruginosa Within the US Bronchiectasis and NTM Research Registry
Aksamit, Timothy R. , Barker, Alan F., Eden, Edward , DiMango, Angela, Fennelly, Kevin P. , Johnson, Margaret M. , Knowles, Michael R. , McShane, Pamela J. , Noone, P.G., O’Donnell, Anne E., Olivier, K.N., Thomashow, Byron, Tino, Gregory , Winthrop, Kevin , O'Donnell, Anne E , Choate, Radmila , Addrizzo‐Harris, Doreen , Basavaraj, Ashwin , Daley, Charles L. , Daniels, M. Leigh Anne , Metersky, Mark L. , Philley, Julie V. , Salathe, Matthias A. , Schmid, A.

Mayo Clinic

D104. PHENOTYPES, PROGNOSTIC TOOLS, AND ADJUNCT THERAPIES IN COUGH, CF AND NON-CF BRONCHIECTASIS | July 7, 2020 | Volume: No volume available | Issue: No issue available | Pages: A7764-A7764

10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a7764 Get It

The Association of Chronic Macrolide Treatment and Incident Isolation of Non-Tuberculous Mycobacteria in Patients with Bronchiectasis
Aksamit, Timothy R. , Barker, Alan F., Eden, Edward , DiMango, Angela, Fennelly, Kevin P. , Johnson, Margaret M. , Knowles, Michael R. , McShane, Pamela J. , Noone, P.G., O’Donnell, Anne E., Olivier, K.N., Thomashow, Byron, Tino, Gregory , Winthrop, Kevin , Metersky, Mark L. , Choate, Radmila , Addrizzo‐Harris, Doreen , Basavaraj, Ashwin , Daley, Charles L. , Daniels, M. Leigh Anne , Philley, Julie V. , Salathe, Matthias A. , Schmid, A.

Mayo Clinic

D12. EPIDEMIOLOGY AND THERAPY IN CF AND NON-CF BRONCHIECTASIS | July 7, 2020 | Volume: No volume available | Issue: No issue available | Pages: A6200-A6200

10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a6200 Get It

Pulmonary Nontuberculous Mycobacterial Infection in Patients in the U.S. Bronchiectasis Research Registry: Use of Antibiotic Therapy and Adverse Events
Henkle, Emily , Aksamit, Timothy R. , Barker, Alan F., Eden, Edward , DiMango, Angela, Fennelly, Kevin P. , Johnson, Margaret M. , Knowles, Michael R. , McShane, Pamela J. , Noone, P.G., O’Donnell, Anne E., Olivier, K.N., Thomashow, Byron, Tino, Gregory , Winthrop, Kevin , O'Donnell, Anne E , Ku, Jennifer H , Metersky, Mark L. , Addrizzo‐Harris, Doreen , Basavaraj, Ashwin , Daley, Charles L. , Daniels, M. Leigh Anne , Choate, Radmila , Philley, Julie V. , Salathe, Matthias A. , Schmid, A.

Mayo Clinic

B106. BREAKTHROUGHS IN NTM DIAGNOSIS AND TREATMENT | July 7, 2020 | Volume: No volume available | Issue: No issue available | Pages: A4358-A4358

10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a4358 Get It

NCCN Guidelines Insights: Rectal Cancer, Version 6.2020
Benson, Al B. , Al-Hawary, Mahmoud M. , Arain, Mustafa A., Chen, Yi‐Jen , Ciombor, Kristen K. , Cooper, Harry S. , Deming, Dustin A. , Garrido‐Laguna, Ignacio , Grem, Jean L. , Hoffe, Sarah E. , Hunt, Steven R., Kirilcuk, Natalie, Krishnamurthi, Smitha , Messersmith, Wells A. , Meyerhardt, Jeffrey A. , Miller, Eric D. , Mulcahy, Mary F. , Nurkin, Steven, Overman, Michael J. , Patel, Hitendra , Pedersen, Katrina S. , Shibata, David , Skibber, John M., Sofocleous, Constantinos T. , Stotsky‐Himelfarb, Eden, Willett, Christopher G. , Johnson-Chilla, Alyse, Gurski, Lisa A., Hubbard, Joleen, Miller, Eric D. , Meyerhardt, Jeffrey A , Pedersen, Katrina , Venook, Alan P. , Cohen, Stacey A. , Gunn, Andrew, Hubbard, Joleen M. , Parikh, Aparna R. , Patel, Hitendra, Saltz, Leonard B. , Schneider, Charles John , Stoffel, Elena M.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | July 7, 2020 | Volume: 18 | Issue: 7 | Pages: 806-815

10.6004/jnccn.2020.0032 | PMID 32634771 Get It

The NCCN Guidelines for Rectal Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with rectal cancer. These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines. These updates include clarifying the definition of rectum and differentiating the rectum from the sigmoid colon; the total neoadjuvant therapy approach for localized rectal cancer; and biomarker-targeted therapy for metastatic colorectal cancer, with a focus on new treatment options for patients with BRAF V600E– or HER2 amplification–positive disease.
The value of genotypic and imaging information to predict functional and structural outcomes in ADPKD
Lavu, Sravanthi , Vaughan, Lisa E. , Senum, Sarah R. , Kline, Timothy L. , Chapman, Arlene B., Mrug, Michal , Braun, William E. , Steinman, Theodore I., Rahbari-Oskoui, Frederic F. , Brosnahan, Godela , Bae, Kyongtae T., Landsittel, Douglas , Torres, Vicente E. , Investigators, the HALT PKD and CRISP Study, Harris, Peter C. , Hogan, Marie C. , Harris, Peter C , Torres, Vicente E , Senum, Sarah R , Hogan, Marie C , Rahbari-Oskoui, Frederic F , Perrone, Ronald D. , Chebib, Fouad T. , Yu, Alan S.L. , Investigators, the HALT PKD and CRISP Study

Mayo Clinic

JCI Insight | July 7, 2020 | Volume: 5 | Issue: 15 | Pages: No page available

10.1172/jci.insight.138724 | PMID 32634120 Get It

BACKGROUND A treatment option for autosomal dominant polycystic kidney disease (ADPKD) has highlighted the need to identify rapidly progressive patients. Kidney size/age and genotype have predictive power for renal outcomes, but their relative and additive value, plus associated trajectories of disease progression, are not well defined. METHODS The value of genotypic and/or kidney imaging data (Mayo Imaging Class; MIC) to predict the time to functional (end-stage kidney disease [ESKD] or decline in estimated glomerular filtration rate [eGFR]) or structural (increase in height-adjusted total kidney volume [htTKV]) outcomes were evaluated in a Mayo Clinic PKD1/PKD2 population, and eGFR and htTKV trajectories from 20–65 years of age were modeled and independently validated in similarly defined CRISP and HALT PKD patients. RESULTS Both genotypic and imaging groups strongly predicted ESKD and eGFR endpoints, with genotype improving the imaging predictions and vice versa; a multivariate model had strong discriminatory power (C-index = 0.845). However, imaging but not genotypic groups predicted htTKV growth, although more severe genotypic and imaging groups had larger kidneys at a young age. The trajectory of eGFR decline was linear from baseline in the most severe genotypic and imaging groups, but it was curvilinear in milder groups. Imaging class trajectories differentiated htTKV growth rates; severe classes had rapid early growth and large kidneys, but growth later slowed. CONCLUSION The value of imaging, genotypic, and combined data to identify rapidly progressive patients was demonstrated, and reference values for clinical trials were provided. Our data indicate that differences in kidney growth rates before adulthood significantly define patients with severe disease. FUNDING NIDDK grants: Mayo DK058816 and DK090728; CRISP DK056943, DK056956, DK056957, and DK056961; and HALT PKD DK062410, DK062408, DK062402, DK082230, DK062411, and DK062401.
Injectable conductive hydrogel restores conduction through ablated myocardium
Zyl, Martin van , Pedrotty, Dawn , Karabalut, Erdem, mfors, Sanna S, Livia, Chris, Vaidya, Vaibhav R. , Sugrue, Alan , Gatenholm, Paul , Kuzmenko, Volodymyr , Livia, Christopher , McLeod, Christopher J. , Behfar, Atta , Asirvatham, Samuel J. , Kapa, Suraj

Mayo Clinic

No container title available | July 6, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.159406900.02369826 Get It

Abstract Introduction: Therapies for substrate-related arrhythmias include ablation or drugs targeted at altering conductive properties or disruption of slow zones in heterogeneous myocardium. Conductive compounds such as carbon nanotubes may provide a novel personalizable therapy for arrhythmia treatment by allowing tissue homogenization. Methods: A nanocellulose-carbon nanotube conductive hydrogel was developed to have conduction properties similar to normal myocardium. Ex vivo perfused canine hearts were studied. Electroanatomic activation mapping of the epicardial surface was performed at baseline, after radiofrequency ablation, and after uniform needle injections of the conductive hydrogel through the injured tissue. Gross histology was used to assess distribution of conductive hydrogel in the tissue. Results: The conductive hydrogel viscosity was optimized to decrease with increasing shear rate to allow expression through a syringe. The DC conductivity under aqueous conduction was 4.3·10-1 S/cm. In 4 canine hearts, when compared to the homogeneous baseline conduction, isochronal maps demonstrated sequential myocardial activation with a shift in direction of activation to surround the edges of the ablated region. After injection of conductive hydrogel, isochrones demonstrated conduction through the ablated tissue with activation similar to baseline in all 4 hearts. Gross specimen examination demonstrated retention of the hydrogel within the tissue. Conclusions: This proof-of-concept study demonstrates that conductive hydrogel can be injected into acutely disrupted myocardium to restore conduction. Future experiments should focus on evaluating long-term retention and biocompatibility of the hydrogel through in vivo experimentation.